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While many drug discovery research programs aim to develop highly selective
clinical candidates, their clinical success is limited because of the complex non-linear
interactions of human brain neuronal circuits. Therefore, a rational approach for identifying
appropriate synergistic multipharmacology and validating optimal target combinations is
desperately needed. A mechanism-based Quantitative Systems Pharmacology (QSP)
computer-based modeling platform that combines biophysically realistic preclinical
neurophysiology and neuropharmacology with clinical information is a possible solution.
This paper reports the application of such a model for Cognitive Impairment In
Schizophrenia (CIAS), where the cholinomimetics galantamine and donepezil are
combined with memantine and with different antipsychotics and smoking in a
virtual human patient experiment. The results suggest that cholinomimetics added to
antipsychotics have a modest effect on cognition in CIAS in non-smoking patients with
haloperidol and risperidone and to a lesser extent with olanzapine and aripiprazole.
Smoking reduces the effect of cholinomimetics with aripiprazole and olanzapine, but
enhances the effect in haloperidol and risperidone. Adding memantine to antipsychotics
improves cognition except with quetiapine, an effect enhanced with smoking. Combining
cholinomimetics, antipsychotics and memantine in general shows an additive effect,
except for a negative interaction with aripiprazole and quetiapine and a synergistic
effect with olanzapine and haloperidol in non-smokers and haloperidol in smokers. The
complex interaction of cholinomimetics withmemantine, antipsychotics and smoking can
be quantitatively studied using mechanism-based advanced computer modeling. QSP
modeling of virtual human patients can possibly generate useful insights on the non-linear
interactions of multipharmacology drugs and support complex CNS R&D projects in
cognition in search of synergistic polypharmacy.
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Introduction
While polypharmacy is more of a rule than an exception in real-
life clinical treatment, preclinical animal models are ill-equipped
to address the issue of comedication because of fundamental
species-specific differences in drug metabolism, the impact of
human-specific genotypes, the different pharmacology of the
drugs for human vs. rodent targets and incomplete pathology (for
a review see, Geerts, 2009).
Cognitive Impairment in Schizophrenia (CIAS) is a major
unmet medical need for this patient population; while psychosis
can be readily managed by the current antipsychotic drug
armentarium, cognitive and negative symptoms are hampering
patients to return to a more normal professional life (Kitchen
et al., 2012). This has prompted the major stakeholders
from industry, regulatory agencies and academia to develop
a regulatory path for cognitive enhancement, resulting in the
development of the Matrics battery (Green and Nuechterlein,
2004). Over the last 15 years, many novel highly selective drugs
have been tested for cognitive enhancement as augmentation
therapy without much success (Dunlop and Brandon, 2015).
Symptomatic treatment has been successful in Alzheimer’s
disease with cholinomimetics and memantine. Galantamine
is an acetylcholinesterase inhibitor (AChE-I) with allosteric
potentiating effects on nicotinic receptors (nAChR) currently
approved for Alzheimer’s Disease (Tariot et al., 2000) and has
been tested for cognitive improvement in schizophrenia (Norén
et al., 2006; Deutsch et al., 2008; Dyer et al., 2008; Sacco et al.,
2008). Donepezil, a pure AChE-I has been studied for cognitive
improvement in schizophrenia withmixed results (Akhondzadeh
et al., 2008; Keefe et al., 2008; Gauthier and Molinuevo, 2013).
On the other hand, memantine is a weak NMDA-antagonist
approved for moderate-to-severe AD (Reisberg et al., 2003) with
preferential affinity against the excitatory-inhibitory synapses
in cortical networks (Kotermanski and Johnson, 2009). The
effect of these compounds in CIAS has yielded equivocal results.
Possible reasons for the lack of clear results include non-
trivial pharmacodynamic relationships between the investigative
drugs and the different baseline antipsychotics. For instance,
some antipsychotics such as olanzapine and clozapine affect
the muscarinic cholinergic receptors; indeed olanzapine is a
documented antagonist ofM1, M2, M3, M4, andM5 mAChRwith
respective affinities of 26, 18, 52, 17, and 20 nM (Bymaster et al.,
Abbreviations: 5HTTLPR, Serotonin transporter promotor: long vs.
short isoform; ACh, acetylcholine; AChE, acetylcholinesterase; AChE-I,
acetylcholinesterase inhibitors; CIAS, Cognitive Impairment in Schizophrenia;
COMT, Catechol-O-Methyl Transferase; CYTP450, Cytochrome P450 enzyme;
DA, Dopamine; dlPFC, dorso-lateral Prefrontal Cortex; EPS, Extra-pyramidal
symptoms; GABA, gamma-amino butyric acid; GPCR, G-protein coupled
receptors; mAChR, muscarinic acetylcholine receptor; MATRICS, Measurement
And Treatment Research to Improve Cognition in; Schizophrenia; nAChR,
nicotinic acetylcholine receptor; NMDA, N-methyl-D-aspartate (glutamate
receptor subtype); PBPD, Physiology-based pharmacodynamic modeling;
PBPK, Physiology-based pharmacokinetic modeling; PDSP, Psycho-active
Drug Screening Program; PET, Positron Emission Tomography; PFC,
Prefrontal Cortex; PK/PK, pharmacokinetic-pharmacokinetic; QSP, Quantitative
Systems Pharmacology; RBANS, Repeatable Battery for the Assessment of
Neuropsychological Status; R&D, (Pharmaceutical) Research and Development.
1996). Therefore, it is to be expected that the dose-response of
cholinomimetics in CIAS might be highly dependent upon the
different antipsychotics.
To complicate the situation even further, anticholinergics are
often used in treating the symptoms of extrapyramidal motor
symptoms and can affect the cognitive function substantially
(Ogino et al., 2014). In addition, a disproportionate fraction
of schizophrenia patients tend to smoke (Dalack et al., 1998),
adding more complexity to the pharmacodynamic interaction of
cholinomimetics at the level of nicotinic receptors.
A recent paper suggested that the combination of memantine
and AChE inhibitors, in particular galantamine, would show
a bigger effect in CIAS because of their complementary
pharmacology on pyramidal cells and interneurons (Koola et al.,
2014).
Testing such a combination therapy is likely beyond the
capability of preclinical animal testing due to the complexity
and combinatorial challenges of the trial design. To explore
the possible clinical applications of this combination therapy,
other approaches need to be explored. In this paper we propose
an advanced version of a computer-based Quantitative Systems
Pharmacology (QSP) platform, a mechanism-based computer
model of the relevant humanized cortical networks that has been
developed for clinical readouts in psychiatry and neurology, and
calibrated with group average clinical data. Such an approach
is similar to Physiology-Based PharmacoDynamic (PBPD)
Modeling in line with new terminology around Physiology-Based
Pharmacokinetic Modeling (PBPK) and is gaining traction in
pharmaceutical research and development. The platform has
been able to blindly, prospectively and correctly predict an
unexpected clinical outcome in schizophrenia and Alzheimer’s
disease (AD) (Geerts et al., 2012; Nicholas et al., 2013; Liu et al.,
2014) and has been calibrated for clinical cognitive outcomes in
conditions of chronic schizophrenia (Geerts et al., 2013).
Testing the platform in a number of practical clinical
situations with known outcomes, such as the augmentation
therapy of cholinomimetics and memantine on antipsychotics is
mandatory to help constrain the platform. Once calibrated and
constrained, with human clinical data, this QSP approach can
then be used in rationally designed multi-target drug discovery
programs.
Methods
We use a previously described (Geerts et al., 2013) biophysically
realistic and mechanism-based QSP platform to simulate the
impact of augmentation therapy with cognitive enhancers in
virtual schizophrenia patients. This QSP platform has been
calibrated against observed clinical effects on the N-back
working memory test with various therapeutic interventions
in diverse patient populations and recapitulates the negative
pharmacodynamic clinical effect of risperidone augmentation
on clozapine. Basically, the platform consists of a receptor
competition model that allows accurate quantification of drug
target exposure, a biophysically realistic neuronal network that
captures the microarchitecture of a cortical column and a
calibration module that relates computer model outcome to
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actual clinical results. The platform includes the neurophysiology
of over 30 CNS targets, ranging from catecholamine GPCR over
various glutamate, GABA receptors and ligand and voltage-gated
ion channels to enzymes such as Catechol-O-methyl transferase
(COMT) and PDE10 and neurotransmitter transporters.
Defining Target Exposure in Quantitative
Systems Pharmacology Model
The receptor competition model (Spiros et al., 2010; Spiros
and Geerts, 2012) calculates the degree of activation of various
postsynaptic receptors (dopamine, serotonin, norepinephrine,
and cholinergic neurotransmitters) in the presence of
antipsychotics. The affinity of the parent molecule and its
major metabolite for both pre- and post-synaptic receptors,
derived from the Psychoactive Drug Screening Program
(Besnard et al., 2012) is used to calculate the competition with
endogenous neurotransmitters. The presynaptic autoreceptor
neurophysiology properties are calculated from preclinical
data using fast-cyclic voltammetry constrained with clinical
imaging data (Nicholas et al., 2013). The functional intrasynaptic
concentration of the specific antipsychotic is determined from
calculating the concentration that corresponds to the clinically
observed displacement of a radio-active D2R specific PET
tracer, such as raclopride (Spiros et al., 2012). We assume
regular clinical doses 400 and 600mg, i.e., 6mg risperidone,
10mg haloperidol, 15mg olanzapine, 200 quetiapine, and 30mg
aripiprazole.
Quantitative Systems Pharmacology Model for
Cognitive Impairment in Schizophrenia
The QSP model consists of a network of 80 four-compartment
pyramidal and 40 two-compartment interneurons with the effects
of dopaminergic, serotonergic, noradrenergic and cholinergic
modulation (including a spatio-temporal receptor statemodel for
allosteric modulation of the different nicotinic ACh receptors)
and has been described in detail elsewhere (Geerts et al., 2013).
A subset of pyramidal cells is stimulated for a very short
period at a certain time point, reflecting a sensory stimulus
typical of a working memory paradigm. The actual membrane
potential of each compartment can be calculated from the actual
conductances, which are dependent upon the activation level of
various G-protein coupled receptors. The resulting state diagram
shows a synchronized firing of the cells during 5–10 s after
they have been stimulated for a short period (100ms). While
this computational neuroscience model has been designed using
in vivo electrophysiological single-unit recordings in non-human
primates (Williams and Goldman-Rakic, 1995) performing a
working memory task and therefore probably only reflects the
maintenance phase, the outcome could be generalized to the
strength of a memory trace (Roberts et al., 2012; Geerts et al.,
2013). We have shown previously that the duration of this
synchronized firing correlates well with actual 2-Back working
memory task in a variety of experimental interventions in
humans (Geerts et al., 2013).
Schizophrenia pathology is implemented using insights from
human neuroimaging, genetic and neuropathology data and
includes a hypodopaminergic cortical D1R tone (Durstewitz
and Seamans, 2008), NMDA-R hypofunction (Coyle, 2006)
documented by a hypocortical-hyperstriatal imbalance in
metabolic imaging (Meyer-Lindenberg et al., 2002), a GABA
deficit (Volk and Lewis, 2002) applied here to the network
interneurons, and a noisier background signal (Winterer
et al., 2000), resulting in a clinical cognitive deficit which is
dependent upon the cognitive domain, but on average is 1.5
standard deviations lower than healthy controls (Saykin et al.,
1994). The pathology in the computer model leads to a similar
deficit between a “healthy environment” and the schizophrenia
condition.
Implementation of Pharmacology for Cognitive
Enhancers
Donepezil is an AChE-inhibitor with a Ki of 20 nM while
galantamine inhibits AChE-I with a much lower affinity of
800 nM and in addition weakly and allosteric potentiates α7
and α4β2 nAChR (Woodruff-Pak et al., 2002). Imaging studies
with 11C-PMP have suggested that 10mg donepezil and 24mg
galantamine lead to brain AChE-inhibition levels of 35%
(Shinotoh et al., 2001; Darreh-Shori et al., 2008). These clinically
observed inhibition levels can be used to calculate the daily
dose to affect 50% brain AChE-inhibition, which corresponds
to 18.5mg for donepezil and 44.5mg for galantamine, resulting
in inhibition levels of 20% for 5mg donepezil, 15% for 8mg
galantamine and 24% for 16mg galantamine. ACh half-life, T, in
the cholinergic receptor competition model is then calculated as
T0/(1-Enzyme inhibition), with T0 being the half-life in untreated
patients. The AchE is one of the fastest enzymes in the human
body (Iwanaga et al., 1994), leading to a half-life in the untreated
situation of 5ms. This leads to ACh half-lives of 6.9 and 7.7ms for
donepezil at 5 and 10mg and to half-lives of 5.9, 6.8, and 7.7ms
for galantamine at 8, 16, and 24mg.
In addition, galantamine has a small allosteric potentiating
effect on nAChR (Woodruff-Pak et al., 2002), which we
implemented as a 5, 10, or 15% (respectively for 8, 16, and 24 mg)
relative increase in both α7 nAChR and α4β2 nAChR activation
levels.
Implementation of Smoking
As a disproportionally large fraction of schizophrenia patients
smoke (Dalack et al., 1998), we implement the effect of nicotine
on both α4β2 nAChR and α7 nAChR. Nicotine has a much
higher affinity for α4β2 nAChR than for a7 nAChR and imaging
studies with the PET radiotracer 18F-2-Fluoro-A85380 showed
an almost complete saturation of α4β2 nAChR in smokers (Brody
et al., 2006). We assume an increase in α4β2 nAChR activation
of 20% as the receptors are already naturally active. However,
this level of α4β2 nAChR activation, together with the continuous
nicotine exposure likely overall leads to receptor desensitization
(Grady et al., 2012). Because α4β2 nAChR regulates GABA
release (McClure-Begley et al., 2009; Zappettini et al., 2011) we
implement the desenitization induced by the smoking condition
as a two-fold decrease in GABA conductances, leading to a
greater firing of the network. Given the relative much lower
affinity of nicotine for the α7 nAChR (20,000 nM vs. 100 nM)
(Buisson et al., 1996), we assume smoking does not affect α7
nAChR. Note that the amount of ACh bound to α4β2 (and of α7)
nAChR is further determined by the galantamine or donepezil
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mediated AChE inhibition in addition to inhibition of the
presynaptic M2mAchR autoreceptor by specific antipsychotics,
such as olanzapine. In ourmodel, this is illustrated by the fact that
binding of ACh to α4β2 nAChR ranges from 24% (non-smoking
patient on haloperidol) to 62% (olanzapine in smoking patients
on 24mg galantamine).
Implementation of Memantine Pharmacology
Memantine is a relatively weak NMDA-R inhibitor that has a
larger affinity for the NMDA-NR2C/2D subunit (Kotermanski
and Johnson, 2009) in physiological conditions. Based upon
the observation that the NR2C/2D subunits are preferentially
located on inhibitory interneurons (Monyer et al., 1994) in rats,
memantine’s pharmacology is implemented using a two-fold
greater inhibition of the NMDAR on interneurons as compared
to the NMDAR on pyramidal cells.
Data further suggest that the functional memantine
concentration in the human brain is relatively small; in our
earlier paper on the cognitive model (Roberts et al., 2012) for
Alzheimer’s Disease, a 1% decrease in gNMDA on interneurons
resulted in a selective positive impact on moderate to severe AD
cases but not in the situation of mild cases, suggesting that such
an inhibition corresponded to the clinical dose of 20mg.
Implementation of Pharmacological Profile of
Antipsychotics
The affinity parameters for each individual drug and
neurotransmitter for human receptors were derived from
the standardized PDSP database (http://pdsp.med.unc.edu/
indexR.html) (Besnard et al., 2012). Importantly, the active
moiety of antipsychotics, taking into account the pharmacology
of metabolites was used (see Figure 1). We took great care
in determining the functional intrasynaptic concentration
of the various antipsychotics using published 11C-raclopride
displacements observed with specific antipsychotic dose
combinations using the receptor competition model, described
above.
Results
Augmentation Therapy with Memantine
We studied the effect of increasing memantine doses on the
performance of the in silico network for CIAS in the presence
of antipsychotics. Figures 2A,B shows the effect of memantine
on the estimated 2-back working memory outcomes, respectively
in the absence and presence of nicotine. In the absence of
smoking, with the exception of quetiapine, all drugs improve
cognitive readout with increasing memantine doses with the
greatest effect observed for aripiprazole (from 69 accuracy to
81% in a 2-back test). For smoking conditions, the increase in
frequency of accurate responses as a function of the optimal
memantine dose is amplified for Risperidone (maximal increase
from 5 to 14%), Haloperidol (maximal effect increases from 5 to
12%) and olanzapine (maximal effect from 6 to 11%), but not
for aripiprazole and quetiapine. Note that this maximal effect
happens atmemantine doses of 40mg. At clinically relevant doses
of 20mg, the effect is about half as much.
Augmentation Therapy with AChE-I
We then simulated the effect of augmentation strategy with
ACh inhibitors added to antipsychotics on cognitive outcome
(Figure 3), both in the absence and presence of nicotine. In
non-smokers, AChE-I dose-dependently improved cognitive
outcomes with risperidone, aripiprazole (donepezil only) and
haloperidol, with only the 24mg galantamine showing a robust
improvement of >10% in correct responses. In the presence of
olanzapine and aripiprazole with galantamine, a tendency was
observed for an inverse U-shape dose-response. In the presence
of quetiapine, increased AChE-I worsened responses.
Smoking tended to increase the procognitive effect as a stand
alone (i.e., without cholinomimetics) and in the presence of
risperidone, haloperidol and aripiprazole (donepezil only). For
instance the fraction of correct responses went up from 66 to 71%
for risperidone with 24mg galantamine. However, smoking also
tended to diminish the cognitive response when augmented with
quetiapine and olanzapine.When aripiprazole is augmented with
galantamine, smoking shifted the peak response of the inverse
U-shaped curve.
Augmentation Therapy with a Combination of
Memantine and AChE-I
This section deals with the simulation of combination therapy of
memantine with cholinomimetics on cognitive outcomes. Note
that we simulate the outcome of up to five agents in the same
patient, i.e., the parent molecule and active metabolite of an
antipsychotic, an AChE-I such as donepezil and galantamine,
memantine and nicotine. This is a situation that is often
encountered in clinical practice.
From the data a complex picture emerges, ranging from a
negative effect (adding AChE-I lowers the effect of memantine)
with quetiapine and aripiprazole, to an additive effect with
risperidone (see Table 1). Synergism is clearly observed with
olanzapine and in some cases with haloperidol in the non-
smoking case and with haloperidol in the smoking condition.
Figure 4 shows a dose-response of memantine on cognitive
effects in the presence of olanzapine, and with donepezil or
galantamine. Memantine increases cognitive effects dose-
dependently in the absence of the AChE-I and the slope (in
% correct on the 2-back WM test for 0–40mg of memantine)
of 0.08 is increased to 0.23 and 0.34 when adding donepezil
5 and 10 mg, respectively. When adding galantamine, the
slope is increased to 0.13, 0.30, and 0.16 for 8, 16, and 24mg,
respectively. This suggests a synergistic effect with increasing
concentrations of donepezil and galantamine, although at
the highest galantamine dose of 24mg the effect is somewhat
attenuated. This synergistic effect with olanzapine however
disappears in the smoking conditions.
An interesting pattern emerges with regard to different doses
of quetiapine. In the non-smoking condition, memantine has
a clear beneficial effect on cognition in the absence of any
AchE-I with a tendency for greater effect at greater quetiapine
doses. Adding donepezil or galantamine reverses this effect at all
quetiapine (200–600mg daily) doses into a negative interaction,
i.e., cognitive performance drops with increasing memantine
dose. The negative interaction decreases slightly as the quetiapine
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FIGURE 1 | Complex pharmacology of antipsychotics and their major metabolites (forming the active moiety of currently used antipsychotic
medication) illustrated by the pKa (−10logKi) against the human receptors, where Ki is the affinity of the drug determined by tracer displacement
studies. More peripheral readouts correspond to higher affinities. Data are derived from the standardized PDSP database (http://pdsp.med.unc.edu/indexR.html). It is
clear that many antipsychotics have complex pharmacologies leading to non-linear interactions in the human networks. (A) pharmacology of active moiety of
aripiprazole, haldoperidol, and olanzapine, (B) pharmacology of risperidone and quetiapine.
FIGURE 2 | Effect of increasing memantine dose on anticipated N-back working memory tests outcome (% correct responses in a 2-Back working
memory test) in the presence of the five antipsychotics. (A) Non-smokers, (B) smokers. The simulations suggest evidence for a dose-dependent effect of
memantine for all antipsychotics except quetiapine. The effect is slightly amplified for patients on nicotine. Note that the maximal dose (40mg) is twice the regular
dose used in Alzheimer patients.
dose increases. This is likely because adding AchE-I to quetiapine
substantially improves cognition; so that further block of the
NMDA receptors with memantine reduces GABA tone and
drives the network to fire at a very high frequency determined
only by the refractory period of the pyramidal neurons, reducing
the variability of the interspike distribution and the information
bandwidth.
In smoking conditions, the slope of cognitive improvement
with memantine without AchE-I is much smaller for all
quetiapine doses, because the baseline performance of smoking
and quetiapine is already higher than in the non-smoking
condition. Adding AchE-I in the smoking condition to
quetiapine and memantine has a relative smaller negative effect
than in the non-smoking condition, although the absolute values
of the slopes are similar. This illustrates the complex non-linear
pharmacodynamic interactions between different comedications.
Table 1 shows the slopes of the memantine dose-response
with donepezil and galantamine in the presence of specific
antipsychotics and smoking/no-smoking conditions. As
mentioned above, there is a synergistic effect in non-smokers
on olanzapine and in smokers treated with haloperidol for both
donepezil and galantamine.
Discussion
This study addresses the question of a suggested synergistic
interaction between AChE-I such as donepezil and galantamine
and memantine on cognitive readouts in schizophrenia (Koola
et al., 2014) by simulating real-life treatment combinations,
including the effect of smoking. We approached this through a
mechanism-based QSP computer modeling approach where the
pathology of CIAS is combined with the pharmacology and target
exposure of the respective drug combinations.
Combination of AChE-I with Antipsychotics
The combination of AChE-I with antipsychotics shows a number
of interesting and unexpected outcomes. The 24mg galantamine
has a higher response than any of the two doses of donepezil
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TABLE 1 | Slopes of the memantine dose-response for non-smokers and
smokers, calculated from the trendline of the dose-responses in the
different conditions and comparing the effect of adding 5 and 10mg
donepezil and 8, 16, and 24mg galantamine to memantine in the presence
of five different antipsychotics (RIS, risperidone; QUE, quetiapine; OLA,
olanzapine; ARI, aripiprazole, HAL, haloperidol).
Stand-alone DON5 DON10 GAL8 GAL16 GAL24
MEM 0.13 0.16 0.08 0.18 0.07 0.02
RIS NoSmok 0.10 0.05 0.11 0.09 0.10 0.14
QUE NoSmok 0.06 − 0.01 −0.05 0.00 0.00 −0.01
QUE400 NoSmok 0.09 0.03 − 0.03 0.01 −0.07 0.06
QUE600 NoSmok 0.10 0.03 −0.01 0.01 −0.07 0.09
OLA NoSmok 0.08 0.23 0.29 0.09 0.21 0.07
ARI NoSmok 0.23 0.09 0.13 0.12 0.04 −0.01
HAL NoSmok 0.12 0.16 0.18 0.16 0.21 0.16
MEM-SMOK 0.13 0.12 − 0.01 0.13 0.23 0.12
RIS SMOK 0.09 0.04 0.07 0.07 0.08 0.18
QUE SMOK 0.02 0.00 −0.02 −0.01 −0.03 −0.03
QUE400 SMOK 0.05 0.00 − 0.03 0.00 − 0.04 −0.04
QUE600 SMOK 0.01 −0.02 −0.02 −0.02 −0.03 −0.02
OLA SMOK 0.02 0.00 −0.02 −0.01 −0.03 −0.03
ARI SMOK 0.11 0.05 0.03 0.05 0.04 −0.03
HAL SMOK 0.21 0.20 0.16 0.12 0.16 0.13
The cases with synergy are noted in yellow, while the situation where addition of AChE-I
to memantine worsens the dose-response is noted in red. The other cases suggest a
pure additive effect. From the data a complex picture emerges, ranging from a negative
effect (i.e., lower slopes) in the presence of quetiapine and aripiprazole (in both non-
smoking and smoking conditions) to an additive effect with olanzapine and quetiapine
combined with donepezil in smoking conditions. Synergism is observed with olanzapine
in the non-smoking case with a tendency for synergism in haloperidol non-smokers and
with haloperidol in the smoking condition.
for risperidone and haloperidol, an effect that is sustained in
smokers. Interestingly galantamine shows an inverse U-shape
dose-response with olanzapine in non-smokers; the lowest dose
of 8mg had a higher effect than the highest dose. Smoking also
drives the responses of both donepezil and galantamine into
an inverse dose-response when combined with aripiprazole or
olanzapine. One could argue that the interaction of olanzapine
with the presynaptic M2 mAChR (a Ki of 18 nM) has a
disproportionately larger impact given the affinity of ACh for
the M2 mAChR (which is in the 300 nM range). Blocking the
presynaptic autoreceptor could further increase the release of
Ach beyond the added effect of AChE inhibition which would
then drive the postsynaptic nAChR into desensitization. The
level of free ACh in schizophrenia patients is relatively normal,
in contrast to the reduced free ACh in Alzheimer’s patients,
suggesting that the nAChR work on a very different baseline.
Aripiprazole and quetiapine both have strong 5-HT1A
agonism and lack the inhibition of the presynaptic 5-HT1BR that
is a hallmark of risperidone; these two properties might account
for a relatively good baseline performance as compared to
risperidone. The 5-HT1A pathway has been documented to play
a role in antipsychotic response (Takekita et al., 2015), at least
in negative symptoms. Therefore, the higher ACh tone resulting
from inhibition of the AChE in the presence of quetiapine and
aripiprazole has less dynamical range to improve.
A recent meta-analysis indeed suggest that antipsychotics do
indeed have different effects on cognition (Désaméricq et al.,
2014), with quetiapine having the greatest beneficial impact on
global cognitive score, attention and speed of processing.
The effect of adding AChE-I to antipsychotics on cognition
has been studied extensively in clinical trials with effect sizes
in the range 0.4–0.6 (Ribeiz et al., 2010; Choi et al., 2013).
Studies with donepezil have yielded controversial and mixed
results, from positive results (Zhu et al., 2014) to negative
results (Kohler et al., 2007; Keefe et al., 2008) with similar
negative (Dyer et al., 2008; Lindenmayer and Khan, 2011)
and positive results (Schubert et al., 2006; Buchanan et al.,
2008) or no effect (Lee et al., 2007) for galantamine leading to
the overall perception that these drugs only work marginally
or not at all. Our modeling suggests that the nature of
the antipsychotic and the condition of smoking does matter.
In non-smokers, donepezil and galantamine work best with
risperidone, haloperidol, aripiprazole, and olanzapine, but not
with quetiapine. In smokers, both galantamine and donepezil
enhance cognition with risperidone and haloperidol but have
an inverse U-shape dose-response in olanzapine (lower AchE-
I doses work best) while there is no effect in aripiprazole and
quetiapine. Interestingly high-dose galantamine is inferior to
placebo for a number of cognitive readouts in schizophrenia
when added to antipsychotics (Dyer et al., 2008). Possible
explanations for these observations include the interaction
of olanzapine with the muscarinic receptors, especially the
presynaptic M2 mAChR autoreceptor. This would affect the
amount of presynaptically released ACh and therfore interfere
in a complex way with the increased half-life of ACh with
AChE-I and the allosteric modulatory effect of galantamine. It
is of interest to note that the trials with donepezil that showed
some efficacy for donepezil, had risperidone and olanzapine
as baseline medication (Akhondzadeh et al., 2008; Zhu et al.,
2014) with a majority of patients on the lower donepezil dose
of 5mg.
Two trials with galantamine (Schubert et al., 2006;
Lindenmayer and Khan, 2011) added to risperidone showed
opposite effects. It is worthwhile to examine these two clinical
trials in more detail. The positive Schubert trial was a short
duration, 8 week trial (n = 16), almost all smokers with an
average risperidone dose of 5.4mg (with patients on risperidone
for almost 3 years) where anticholinergics were excluded and
showed a clear clinical and statistical benefit in delayed memory
and attention on the RBANS scale. The negative Lindenmayer
trial was a 52-week study of long-acting injection Risperidone
(25 and 50mg) in 32 patients in which galantamine was titrated
up to 24 mg; no data on smoking were available. Anticholinergics
were allowed for treatment of EPS side-effects, but no data are
available on the frequency of this comedication.
Possible clinical trial design differences in these two studies
leading to the opposite outcomes include the fraction of smokers
(smoking tends to amplify galantamine’s effect on cognition) and
the somewhat lower dose of 25mgRis Consta in the Lindenmayer
study as compared to 6mg oral risperidone. Sensitivity analyses
in the model show that lower risperidone doses tend to perform
better in the cognitive model, leaving somewhat less dynamic
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FIGURE 3 | Simulated clinical outcome (% correct responses in a 2-Back working memory test) for the combination of various cholinomimetics
(donepezil and galantamine) with different antipsychotics in non-smoking schizophrenia patients (A) and in smoking schizophrenia patients (B). Both
galantamine and donepezil show a dose-dependent improvement in the presence of risperidone, aripiprazole, and haloperidol, although the effect sizes differ.
However, there is no improvement for quetiapine, probably due to the high baseline, and a more complex dose-response for olanzapine. Smoking tends to slightly
enhance the responses of cognition in augmentation therapy with risperidone and haloperidol. However, smoking also tends to slightly decrease the responses of
cognition in augmentation therapy with quetiapine and olanzapine. This is probably due to the many non-linear interactions between cholinergic modulation and the
complex pharmacodynamics of antipsychotics.
FIGURE 4 | Simulated clinical outcome (% correct responses in a
2-Back working memory test) for the combination of memantine and
cholinomimetics (donepezil and galantamine) as augmentation therapy
with olanzapine in non-smoking conditions. The dose-response of
memantine, memantine + donepezil (two doses) and memantine +
galantamine (three doses) are fitted with a linear trendline. The slope of the
memantine dose-response clearly increases when adding donepezil and
galantamine in a dose-dependent way (i.e., with higher donepezil or
galantamine doses), suggesting a synergistic effect.
range for additional effect of pro-cognitive enhancers; this is
partially explained by the anti-cognitive effect of the dose-
dependent presynaptic 5-HT1B autoreceptor block that affects
free 5-HT levels. Attention deficit has indeed been shown to
be correlated with the amount of D2R blockade by risperidone
(Uchida et al., 2009), at least in late-life schizophrenia; therefore
higher doses of risperidone leading to a lower baseline provide a
greater dynamic range for pro-cognitive effects of galantamine.
In general, however, the information available from peer-
reviewed articles usually does not have the granularity needed
to identify the different comedications for individual patients
in the different treatment arms. Exploration of other databases
such as ADNI, where the comedications are given at the level of
individual subjects or the database from electronic health records
from the South London and Maudsley National Health Systems
registry (Kadra et al., 2015) are a possibility to test the QSPmodel
outcomes to real-life situations.
Combination of Memantine with Antipsychotics
The simulations in this paper also suggest that memantine as
augmentation therapy has a very modest effect on cognition
that is enhanced in the smoking conditions. Again the best
response is observed when adding memantine to risperidone and
haloperidol, but at concentrations that are about twice as high as
currently used in Alzheimer’s disease. A meta-analysis of clinical
trials (Kishi and Iwata, 2013) indeed suggests a modest effect of
memantine on cognition in schizophrenia.
It is worthwhile to expand upon the unexpected clinical pro-
cognitive finding of a (weak) NMDA-antagonist. Memantine’s
interaction under in vivo conditions with Mg present, shows a
higher affinity for the NMDA-NR2C subunit on the excitatory-
inhibitory glutamatergic synapses as compared to the NMDA-
NR2A/B subunits that are present on excitatory-excitatory
synapses (Kotermanski et al., 2009). Smoking tends to desensitize
the α4β2 nAChR more than the α7 nAChR; this would lead to
a lower GABA tone as one of α4β2 nAChR mediated processes
regulates the GABA release (McClure-Begley et al., 2009;
Zappettini et al., 2011). Memantine, through its antagonism on
the excitatory-inhibitory glutamatergic synapse, also lowers the
GABA-tone, opening the possibility for an additive or synergistic
mechanism by addressing one of the major pathological
hallmarks of the schizophrenia condition (Volk and Lewis, 2002).
Combination of Memantine and AChE-I with
Antipsychotics
When adding AChE-inhibitors to antipsychotics andmemantine,
the effect greatly depends upon both the nature of the
antipsychotic and the smoking condition. Overall, the effect
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is additive, with the exception of aripiprazole and quetiapine
for both smokers and non-smokers and for olanzapine in the
smoking condition, where addition of AChE-I decreases the
effect of memantine.
A synergistic effect is observed for olanzapine in the non-
smoking condition and for haloperidol in both conditions. The
observation that adding AChE-I to memantine can improve
cognitive readouts is in line with clinical data in Alzheimer’s
patients (Gauthier and Molinuevo, 2013). The inhibition on
the AChE leads to slightly shorter half-life for AChE in the
case of galantamine (5.9ms for 8mg galantamine vs. 6.5ms for
5mg donepezil). The observed lack of differentiation between
donepezil and galantamine could be due to the fact that the
impact of galantamine’s allosteric modulation on nAChR has a
quite limited effect (especially given the low efficacy) and is barely
capable to compensate for the somewhat lower level of AChE-
I. This is in line with clinical observations in the Alzheimer’s
field that suggest no detectable difference in treatment with either
donepezil or galantamine (Tan et al., 2014).
The observation that olanzapine favors a synergistic effect
between memantine and AChE-I points to an important role
for the GABA interneurons in cortical circuits. Olanzapine
has a substantial antagonism at the 5-HT3R that regulates
GABA interneuron firing (Puig, 2004), a property it shares
with clozapine and as such can compensate for the observed
GABA dysfunction in schizophrenia (Volk and Lewis, 2002).
Indeed, as mentioned above, memantine preferentially interacts
with the NMDA receptor subunit on the excitatory-inhibitory
synapses, increased levels of ACh through blocking of the
AChE can activate α4β2 nAChR that regulate GABA release and
galantamine has an additional allosteric potentiating effect at
the same α4β2 nAChR. The fact that the synergism disappears
in smoking olanzapine patients suggests that this interaction is
highly non-linear in nature.
Smoking by itself tends to improve cognitive outcome,
probably through its effect on α4β2 nAChR GABA tone, perhaps
underscoring its capacity for self-medication. Smoking can also
enhance the effect of either memantine or AChE-I in a number
of situations, but with both memantine and AChE-I added to
antipsychotics the effect is hard to predict due to a number of
non-linear interactions. This further underscores the importance
of the excitation-inhibition balance in these cortical networks.
It is of interest to elaborate on the negative pharmacodynamic
interactions of certain conditions. Increasing evidence suggest
that information in the human brain is not encoded in simple
firing rates; examples include oscillatory behavior of local field
potential in the subthalamic nucleus of basal ganglia that code
for motor symptoms (Little et al., 2013; Beudel et al., 2015). Our
model readout also takes into account the interspike variability
of the action potential train(Geerts et al., 2013) which might
explain some of the non-monotonic dose-responses observed
with quetiapine and aripiprazole, where increased firing rate does
not lead to enhanced cognitive performance.
Limitations of the Model
The network is calibrated on a working memory task, represents
only the maintenance phase and therefore probably does not
capture the intricacies of the different cognitive tasks. However,
we would argue that the network also captures the strength of a
memory trace representation that is a necessary step in a number
of other cognitive tasks. For instance, in an episodic memory
task, an existing memory trace needs to be retrieved from its
memory bank and kept for a certain time in memory, although
at a different time scale, to perform calculations and to compare
it to a novel sensory stimulus.
A major issue is the choice of the biological processes and
the changes associated with the pharmacological treatment. For
instance, the allosteric effect of galantamine on nAChR has been
documented to be as high as 70% (Samochocki et al., 2000) but
a later study puts the effect more at 40% and lower (Samochocki
et al., 2003). Furthermore, we have somewhat arbitrarily set the
effect of smoking as a 20% increase in activation. The effect of
such differences can be studied using sensitivity analyses.
Another major limitation is the “blind” pharmacology of
antipsychotic drugs; unlike animal models, the computer model
is bound by the available knowledge of the pharmacology of
the drugs and does not take into account the possible effect of
drugs on targets that are undocumented. However, the functional
concentration of antipsychotics as measured by PET raclopride
radiotracer in clinically relevant situations is in the low nM range,
except for quetiapine. This effectively reduces the probability of
off-target effects that might play a role at higher doses.
This simulation generates average values for “generic” patients
on a fixed dose of an antipsychotic and, memantine and/or
an AChE-I. In real-life practice, doses are often titrated
to the best trade-off between efficacy and side-effects. In
addition, the variability in clinical outcome might be affected
by CYTP450 interaction between the different drugs where
inhibition or stimulation of a CYTP450 enzyme by one drug
might affect the levels of other drugs (so called pharmacokinetic-
pharmacokinetic or PK/PK interactions). Finally, variability
might be a consequence of different genotypes, for instance
the COMTVal158Met and the 5-HTTLPR s/l that all can
affect cognitive outcomes. In principle, the QSP platform
is able to simulate virtual individual patients complete with
PK/PK interactions, different individual doses of the different
drugs and any combination of the common genotypes. As
an example, we have implemented the COMTVal158Met
genotype in the QSP platform using human imaging studies
in unmedicated healthy volunteers as a different half-life of
dopamine and norepinephrine in cortical synapses (Spiros and
Geerts, 2012).
The major message from this simulation exercise is the
unexpected impact of different antipsychotics each with
their own fingerprint of pharmacological activity on the
dose-response of the same drug-drug combination and/or
combined with smoking. The non-linear interactions of drug
pharmacodynamics plays an important role in real-life drug
treatment, as polypharmacy is more the rule than the exception.
This is particularly important when considering the design of
clinical trials; careful consideration of inclusion/exclusion of
comedications can substantially reduce the patient variability
in the different treatment arms and increase the probability
that a clinical signal can be detected. Failure to take these
differential interactions into account might lead to reduction
of the clinical signal as treatment arms become inadvertently
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populated with drugs that do not work or work adversely. We
suspect that this might be one of the causes of clinical trial
failures of drugs tested with augmentation therapy in Cognitive
Impairment with Schizophrenia. Obviously other processes
contribute to the variability in clinical trial outcomes such as
different genotypes, different pathological baselines and PK
variability. In this regard, we would argue that the concept of
chlorpromazine equivalents (Beckmann and Laux, 1990) where
the differentiation between antipsychotics is solely driven by
their dose and their corresponding D2R occupancy, although
very handy and appealing because of its simplicity, might need a
substantial correction.
An additional collorary is that new drugs with a specific
selective pharmacology aimed at augmentation therapy could
only be combined with specific antipsychotics, because of
negative pharmacodynamic interaction of other antipsychotics
with specific drug pharmacology of the new investigative
compound. In addition, smoking through its effect on nicotinic
receptors can significantly affect cognitive outcome. The
results of this paper suggest that the complex poly-pharmacy
profile of marketed antipsychotics can lead to non-linear
pharmacodynamics interactions beyond their simple D2R
occupancy and that this can significantly impact clinical
outcome.
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